The contribution of RARRES3 to differentiation over self-renewal suggests that reduced RARRES3 expression would also be predictive for cancer patients that exhibit therapy-resistant tumors.
Indeed, persons with late syphilis [ 34] and those with HIV not on antiretroviral therapy exhibit slower serological responses [ 32].
Experimental therapies in prostate cancer such as targeted agents, immunotherapy, and vaccine therapy exhibit limited efficacy and no improvement in survival [ 1].
Indeed, residual breast cancer cells isolated from patients who have received conventional therapy exhibit stem cell-like features and express increased antioxidant enzymes [ 4, 5, 31].
Cancer patients receiving anti-VEGF therapy exhibit pre eclampsia-like sympre eclampsia-likethat decreasymptomsvailability of VEGF causuggestingsympthat (Kabbinavar et al., 2003).
Postmenopausal women taking estrogen replacement therapy exhibit a reduced risk of hip and knee OA, compared with those not taking it [ 40, 41].
Multiple comparisons between progression-free survivals (PFS) show that xenografts treated with the combination of endocrine and anti-HER2 therapy exhibit better response than with either anti-HER2 therapy alone (Additional files 3 and 4).
Diabetes increases long-term mortality following MI [ 3, 4], and patients requiring glucose-lowering therapy exhibit a cardiovascular risk of the same magnitude as patients without diabetes with a prior myocardial infarction, regardless of gender and diabetes type [ 5].
It seems that all but two of the included physical agents (MA and ultrasound therapy), exhibit statistically significant effects over placebo within 1 4 weeks, regardless of what doses and treatment procedures were being used.
Despite generally high cure rates in patients with metastatic germ cell cancer, patients with progressive disease on first-line cisplatin-based chemotherapy or with relapsed disease following high-dose salvage therapy exhibit a very poor prognosis.
